Hepatitis B component does not interfere with the immune response to diphtheria, tetanus and whole-cell Bordetella pertussis components of a quadrivalent (DTPw-HB) vaccine: a controlled trial in healthy infants

Immunogenicity of two diphtheria-tetanus-whole cell pertussis-hepatitis B vaccines in infants: A comparative trial

“…9 In Spain, all subjects responded well, when a tetravalent vaccine (SmithKline Beecham Biologicals, Belgium) was given at 3, 5 and 7 mo of age. 10 However, opposite to our study, neonatal HB vaccination was not accomplished in these studies.…”

“…6,[8][9][10] With this background we were happy to find that the Indian-made tetravalent DTwP-HB combination competed well in these respects with the European vaccine. In fact, GMT of anti-tetanus antibodies was higher with the Indian vaccine.…”

“…The immunological results are in line with earlier studies on DTPw-HB. [8][9][10] In Czech Republic, a new DTPw-HB vaccine HBsAg positive. Thus, 250 vaccinees remained to be analyzed; 123 had received the Indian and 127 the European vaccine.…”

Safety and immunogenicity of diphtheria-tetanus-pertussis vaccine and hepatitis B vaccine as a new tetravalent combination (DTwP/HB) administered alone and at separate sites (DTwP & HB) including comparison with standard commercially available combination vaccine in Indian infants 6-14 weeks of age

“…These findings are in accordance with the results of earlier studies. 12,20 Composition of vaccines (0.5 ml). DTwP/HB (Q-Vac) Vaccine: Immunogenicity assessment.…”

“…7 International studies have shown that the HB component does not interfere with the immune response to DTwP components in a tetravalent vaccine. 8 An open, comparative study was conducted at two tertiary care hospitals in India to assess immunogenicity and reactogenicity following administration of the DTwP/HB combination vaccine (Q-Vac) alone and DTwP and HB (Genevac B) vaccines at separate sites. These vaccines manufactured by Serum Institute of India, Ltd. (SIIL), Pune were compared with DTwP/ HB vaccine (Tritanrix HB) manufactured by GlaxoSmithKline (GSK) in infants aged 6-14 weeks.…”